For patients with nephrolithiasis, sodium-glucose cotransporter-2 (SGLT-2) inhibitor use is associated with a reduction in recurrence.

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

Lemons (Citrus limon) are a citrus fruit known for their tangy and sour taste and bright yellow color. They're packed with ...

Adults with hypoparathyroidism treated with TransCon PTH in the phase 3 PaTHway open-label trial extension demonstrated ...

New study reports protective effect among people with type 2 diabetes Kidney stones and the systemic conditions associated with them have a major impact on health and the economy in the US and ...

"The findings from these target trial emulations indicate that SGLT-2 inhibitors could be a valuable addition to existing ...

Sodium glucose cotransporter 2 inhibitors used to treat diabetes may also reduce the risk of recurrent kidney stones and gout ...

Kidney stones, which are clinically called renal calculi or nephrolithiasis, are deposits of pebble-like material that form in one or both kidneys. These come in different shapes and range in size ...